A
Aethon Therapeutics
A company creating custom antibody therapeutics that unite immunotherapy and targeted therapy
About Aethon Therapeutics
Aethon Therapeutics is a pioneering biotechnology company focused on developing advanced treatments for drug-resistant cancer. The company engineers novel antibodies designed to be used in combination with targeted therapies, aiming to selectively eradicate cancer cells that have become resistant to conventional treatments. Operating in the life sciences sector, Aethon Therapeutics collaborates with leading research institutions like NYU Langone Health to drive innovation in cancer treatment. The business model revolves around the development and commercialization of these specialized antibodies, generating revenue through partnerships, licensing agreements, and direct sales to healthcare providers. By integrating targeted and immune therapies, Aethon Therapeutics aims to transform cancer treatments into potential cures, offering hope to patients with limited options.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2023 | $30M | $120M | NYU Langone Health · Apple Tree Partners | ↗ |
| SPINOUT✓Other financing | Jan 2022 | $0 | — | NYU Langone Health | — |
Growth signals
Latest recorded traffic for Aethon Therapeutics is 4K monthly website visits, up 66.7% over the last three months. Aethon Therapeutics's team grew 6.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Aethon Therapeutics in the New York City ecosystem
The Aethon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Apple Tree Partners
NYU Langone Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aethon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aethon Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









